Billing and Coding: Guidance for Anti-Inhibitor Coagulant Complex (AICC) National Coverage Determination (NCD) 110.3
National · Effective Oct 1, 2026
1 active Medicare policy lists J7190, and 6 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
National · Effective Oct 1, 2026
6 policies from 6 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Policy | Effective | Status of J7190 |
|---|---|---|
| Advate, Adynovate, Afstyla, Altuviiio, Eloctate, Esperoct, Jivi, Kogenate FS, Kovaltry, Obizur, Novoeight, Nuwiq, Recombinate, Xyntha (antihemophilic factor [recombinant]) Hemofil M, Koate-DVI (antihemophilic factor [plasma de | Aug 1, 2024 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J7190 |
|---|
| Hemophilia Products – Factor VIII (Hemophilia A, Congenital and Acquired): Advate, Adynovate, Afstyla, Eloctate, Helixate FS, Hemofil M, Koate-DVI, Kogenate FS, Kovaltry, Monoclate-P, Novoeight, NUWIQ, Recombinate, Xyntha, Obizur, Jivi and Esperoct | Jul 13, 2020 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Policy | Effective | Status of J7190 |
|---|---|---|
| Standard Half-life Factor VIII Products: Advate, Afstyla, Hemofil M, Koate DVI, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, and Xyntha Listed in Moda Health's provider indexes for Oregon, Alaska, Idaho, Texas. The document does not establish the member's state or line of business. | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J7190 |
|---|---|---|
| Clotting Factors, Coagulant Blood Products, & Other Hemostatics | Oct 1, 2026 | Covered |
| Policy | Effective | Status of J7190 |
|---|---|---|
| Clotting Factors, Coagulant Blood Products, & Other Hemostatics | Oct 1, 2026 | Covered |
| Policy | Effective | Status of J7190 |
|---|---|---|
| Clotting Factors, Coagulant Blood Products, & Other Hemostatics | Oct 1, 2026 | Covered |